Your browser doesn't support javascript.
loading
Mechanical Thrombectomy Outcomes With or Without Intravenous Thrombolysis.
Gariel, Florent; Lapergue, Bertrand; Bourcier, Romain; Berge, Jérôme; Barreau, Xavier; Mazighi, Mikael; Kyheng, Maéva; Labreuche, Julien; Fahed, Robert; Blanc, Raphael; Gory, Benjamin; Duhamel, Alain; Saleme, Suzana; Costalat, Vincent; Bracard, Serge; Desal, Hubert; Detraz, Lili; Consoli, Arturo; Piotin, Michel; Marnat, Gaultier.
Afiliação
  • Gariel F; From the Department of Diagnostic and Interventional Neuroradiology, University Hospital of Bordeaux, France (F.G., J.B., X.B., G.M.).
  • Lapergue B; Department of Stroke Center, University of Versailles and Saint-Quentin-en-Yvelines, Foch Hospital, Suresnes, France (B.L., A.C.).
  • Bourcier R; Department of Diagnostic and Interventional Neuroradiology, Guillaume et René Laennec University Hospital, Nantes, France (R.B., H.D., L.D.).
  • Berge J; From the Department of Diagnostic and Interventional Neuroradiology, University Hospital of Bordeaux, France (F.G., J.B., X.B., G.M.).
  • Barreau X; From the Department of Diagnostic and Interventional Neuroradiology, University Hospital of Bordeaux, France (F.G., J.B., X.B., G.M.).
  • Mazighi M; Department of Diagnostic and Interventional Neuroradiology, Rothschild Foundation, Paris, France (M.M., R.F., R.B., M.P.).
  • Kyheng M; Department of Biostatistics, University Lille, CHU Lille, EA2694-Santé Publique: Epidémiologie et Qualité des Soins, France (M.K., J.L., A.D.).
  • Labreuche J; Department of Biostatistics, University Lille, CHU Lille, EA2694-Santé Publique: Epidémiologie et Qualité des Soins, France (M.K., J.L., A.D.).
  • Fahed R; Department of Diagnostic and Interventional Neuroradiology, Rothschild Foundation, Paris, France (M.M., R.F., R.B., M.P.).
  • Blanc R; Department of Diagnostic and Interventional Neuroradiology, Rothschild Foundation, Paris, France (M.M., R.F., R.B., M.P.).
  • Duhamel A; Department of Biostatistics, University Lille, CHU Lille, EA2694-Santé Publique: Epidémiologie et Qualité des Soins, France (M.K., J.L., A.D.).
  • Saleme S; Department of Diagnostic and Interventional Neuroradiology, University Hospital of Limoges, France (S.S.).
  • Costalat V; Department of Diagnostic and Interventional Neuroradiology, Hôpital Gui de Chauliac, Montpellier, France (V.C.).
  • Desal H; Department of Diagnostic and Interventional Neuroradiology, Guillaume et René Laennec University Hospital, Nantes, France (R.B., H.D., L.D.).
  • Detraz L; Department of Diagnostic and Interventional Neuroradiology, Guillaume et René Laennec University Hospital, Nantes, France (R.B., H.D., L.D.).
  • Consoli A; Department of Stroke Center, University of Versailles and Saint-Quentin-en-Yvelines, Foch Hospital, Suresnes, France (B.L., A.C.).
  • Piotin M; Department of Diagnostic and Interventional Neuroradiology, Rothschild Foundation, Paris, France (M.M., R.F., R.B., M.P.).
  • Marnat G; From the Department of Diagnostic and Interventional Neuroradiology, University Hospital of Bordeaux, France (F.G., J.B., X.B., G.M.).
Stroke ; 49(10): 2383-2390, 2018 10.
Article em En | MEDLINE | ID: mdl-30355117
ABSTRACT
Background and Purpose- Intravenous thrombolysis (IVT) within 4.5 hours of symptom onset is currently recommended before mechanical thrombectomy (MT). We compared functional outcome, neurological recovery, reperfusion, and adverse events according to the use or not of IVT before MT. Methods- This is a post hoc analysis of the ASTER trial (Contact Aspiration Versus Stent Retriever for Successful Revascularization). The primary outcome was favorable 90-day functional outcome defined as a modified Rankin Scale of ≤2. Secondary outcomes were successful reperfusion following all procedures and after the first-line procedure, number of device passes, and change in National Institutes of Health Stroke Scale score at 24 hours. Safety outcomes included 90-day mortality and any symptomatic intracerebral hemorrhage. Results- Three hundred eighty-one patients were included, 250 of whom received IVT before MT (IVT+MT group). There were no significant differences between IVT+MT and MT-alone groups in 90-day favorable functional outcome, in successful reperfusion rate (modified Thrombolysis In Cerebral Infarction 2b or 3), in National Institutes of Health Stroke Scale score improvement at 24 hours, or in hemorrhagic complication rate. The 90-day mortality rate in the IVT+MT group was lower than after MT alone (fully-adjusted risk ratio, 0.59; 95% CI, 0.39-0.88). In a subgroup of patients without anticoagulant medication before stroke onset, we observed in the IVT+MT group a better functional outcome (fully-adjusted risk ratio, 1.38; 95% CI, 1.02-1.89), a higher successful recanalization rate after first-line strategy (fully-adjusted risk ratio, 1.26; 95% CI, 1.05-1.50), and a lower mortality rate (fully-adjusted risk ratio, 0.58; 95% CI, 0.36-0.93). Conclusions- Our results show that IVT+MT patients in the ASTER trial have lower 90-day mortality compared with those receiving MT alone. In a selected population of patients without prestroke anticoagulation, we demonstrated that IVT associated with MT might improve functional outcome and recanalization while reducing mortality rates.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Trombolítica / Hemorragia Cerebral / Acidente Vascular Cerebral / Trombólise Mecânica Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Trombolítica / Hemorragia Cerebral / Acidente Vascular Cerebral / Trombólise Mecânica Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article